339 related articles for article (PubMed ID: 31037448)
1. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.
Sugawara K; Koizumi S; Horikawa Y; Mimori N; Tsuji T; Ishii H; Fujimori S; Onochi K; Watanabe H; Iijima K
J Gastroenterol; 2019 Nov; 54(11):963-971. PubMed ID: 31037448
[TBL] [Abstract][Full Text] [Related]
2. A multicenter prospective study on the prevalence of Helicobacter pylori-negative and nonsteroidal anti-inflammatory drugs-negative idiopathic peptic ulcers in Japan.
Kanno T; Iijima K; Abe Y; Yagi M; Asonuma S; Ohyauchi M; Ito H; Koike T; Shimosegawa T
J Gastroenterol Hepatol; 2015 May; 30(5):842-8. PubMed ID: 25532720
[TBL] [Abstract][Full Text] [Related]
3. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Arkkila PE; Seppälä K; Kosunen TU; Sipponen P; Mäkinen J; Rautelin H; Färkkilä M
Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):93-101. PubMed ID: 15647648
[TBL] [Abstract][Full Text] [Related]
5. Preferential location of idiopathic peptic ulcers.
Iijima K; Kanno T; Abe Y; Yagi M; Asonuma S; Ohyauchi M; Ito H; Koike T; Shimosegawa T
Scand J Gastroenterol; 2016 Jul; 51(7):782-7. PubMed ID: 26854021
[TBL] [Abstract][Full Text] [Related]
6. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
Bianchi Porro G; Parente F; Imbesi V; Montrone F; Caruso I
Gut; 1996 Jul; 39(1):22-6. PubMed ID: 8881802
[TBL] [Abstract][Full Text] [Related]
7. Comparative study: Vonoprazan and proton pump inhibitors in
Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori-negative and non-steroidal anti-inflammatory drugs-negative idiopathic peptic ulcers show refractoriness and high recurrence incidence: Multicenter follow-up study of peptic ulcers in Japan.
Kanno T; Iijima K; Abe Y; Yagi M; Asonuma S; Ohyauchi M; Ito H; Koike T; Shimosegawa T
Dig Endosc; 2016 Jul; 28(5):556-63. PubMed ID: 26866510
[TBL] [Abstract][Full Text] [Related]
9. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan.
Ootani H; Iwakiri R; Shimoda R; Nakahara S; Amemori S; Fujise T; Kikkawa A; Tsunada S; Sakata H; Fujimoto K
J Gastroenterol; 2006 Jan; 41(1):41-6. PubMed ID: 16501856
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Kiyotoki S; Nishikawa J; Sakaida I
Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
[TBL] [Abstract][Full Text] [Related]
11. Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use, and Helicobacter pylori infection.
Ramsoekh D; van Leerdam ME; Rauws EA; Tytgat GN
Clin Gastroenterol Hepatol; 2005 Sep; 3(9):859-64. PubMed ID: 16234022
[TBL] [Abstract][Full Text] [Related]
12. The safety and effectiveness of vonoprazan-based
Ashida K; Honda Y; Sanada K; Takemura Y; Sakamoto S
Expert Opin Drug Saf; 2019 Dec; 18(12):1255-1261. PubMed ID: 31646920
[No Abstract] [Full Text] [Related]
13. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
14. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use.
al-Assi MT; Genta RM; Karttunen TJ; Graham DY
Endoscopy; 1996 Feb; 28(2):229-33. PubMed ID: 8739738
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
[TBL] [Abstract][Full Text] [Related]
16. Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease.
Xia HH; Phung N; Kalantar JS; Talley NJ
Med J Aust; 2000 Nov; 173(10):515-9. PubMed ID: 11194733
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Hou X; Meng F; Wang J; Sha W; Chiu CT; Chung WC; Gu L; Kudou K; Chong CF; Zhang S
J Gastroenterol Hepatol; 2022 Jul; 37(7):1275-1283. PubMed ID: 35342997
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic approaches to gastric and duodenal ulcers: an update.
Dajani EZ; Klamut MJ
Expert Opin Investig Drugs; 2000 Jul; 9(7):1537-44. PubMed ID: 11060758
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
[TBL] [Abstract][Full Text] [Related]
20. What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers?
Hawkey CJ
Eur J Gastroenterol Hepatol; 2000 Jun; 12 Suppl 1():S17-20. PubMed ID: 10929894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
